Generate Biomedicines, Inc.
GENBNASDAQHealthcareBiotechnology
As of Oct 26, 2026 close
- Market cap
- $1.58B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $11.00$22.67
- Volume (live)
- -
- Avg. volume (3M)
- 1.06M
Generate Biomedicines (GENB) Stock Price & Financial Analysis
Generate Biomedicines Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $12.20 - $12.59 |
|---|---|
| 52-Week High | $22.67 |
| 52-Week Low | $11.00 |
| Open | $12.52 |
| Volume (last close) | 340.83K |
| Average Volume (3M) | 1.06M |
| Revenue (TTM) | 32.49M |
|---|---|
| Net Income (TTM) | -234.41M |
| Free Cash Flow (TTM) | -245.88M |
| EPS (TTM) | −$2.39 |
| Profit Margin | -721.56% |
| Operating Margin | -751.19% |
| Return on Equity (ROE) | -51.40% |
| Debt to Equity | 0.14 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 1.58B |
|---|---|
| Shares Outstanding | 128.24M |
| Price to Sales (P/S) | 48.75 |
| Price to Book (P/B) | 3.47 |
| EV/EBITDA | -6.98 |
| 50-Day MA | $15.30 |
|---|
Source: Market prices and company fundamentals. Data as of Oct 26, 2026. Data sources and methodology
Generate Biomedicines at a Glance
As of the Oct 26, 2026 close, Generate Biomedicines (GENB) has a market capitalization of $1.58B. The stock trades at 48.8× sales. Over the trailing twelve months it lost $234.41M on revenue of $32.49M and burned $245.88M of free cash flow. Revenue grew 55.9% year over year.
As of its latest reported balance sheet, it holds $135.36M in cash and securities against $62.63M of debt, a net cash position of $72.73M.
Generate Biomedicines does not currently pay a dividend.
At $12.35 (the Oct 26, 2026 close) it sits near the bottom of its 52-week range of $11.00 to $22.67.
Based on 4 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $26.00, 110.5% above the Oct 26, 2026 close.
Frequently Asked Questions About Generate Biomedicines
What is the current stock price for GENB?
As of the Oct 26, 2026 close, GENB stock trades at $12.35. The 52-week range is $11.00–$22.67, with a day range of $12.20–$12.59.
What is the P/E ratio for GENB?
The P/E ratio (Price-to-Earnings) for GENB is shown in the Key Statistics section. This valuation metric helps compare Generate Biomedicines, Inc. to industry peers.
Does GENB pay dividends?
Generate Biomedicines does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for GENB?
Based on ratings from 4 professional analysts over the last 90 days, the consensus for GENB is Buy. The average 12-month price target is $26.00, a 110.5% upside from the Oct 26, 2026 close of $12.35.
What is the market cap of GENB?
As of the Oct 26, 2026 close, Generate Biomedicines's market capitalization is $1.58B, classifying it as a small-cap company. Generate Biomedicines operates in the Healthcare sector within the Biotechnology industry.